Argo Biopharmaceutical Co., Ltd. (Argo Biopharma), a clinical-stage small interfering RNA (siRNA) therapeutics company, today announced that the U.S. Food and Drug Administration (FDA) has granted ...

A biochemical breakthrough using simple carbon atoms, by Ken Yamada, Ph.D., and Anastasia Khvorova, Ph.D., has dramatically improved the stability and efficacy of a potential oligonucleotide ...

Moore indicated Codexis is scaling up to 100-gram production and aims for 0.5 kilogram by year-end, while also referencing a client’s use of Codexis ligase to manufacture a 3-kilogram batch of ...

This deal adds two more siRNA candidates to GSK’s pipeline, which the company is looking to expand as it looks to offset the impacts of key patent expiries within its portfolio.

The current coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has challenged healthcare facilities globally. Even though the FDA ...

Alnylam Pharmaceuticals and PeptiDream are partnering to develop a peptide-based delivery system for Alnylam’s small interfering RNA (siRNA) therapies that silence gene expression. Alnylam has three ...

Codexis has agreed to manufacture 50 grams of siRNA using its proprietary ECO Synthesis manufacturing platform to support ...

RNA interference using small interfering RNAs (siRNAs) has become a mainstay of functional gene characterization and has generated over a dozen FDA-approved therapeutics and drugs in late-stage ...

RNA interference is a gene regulatory mechanism in which the expression of specific genes is downregulated by endogenous microRNAs or by small interfering RNAs (siRNAs). Although siRNAs have broad ...

siMecA-AGO2 complex inhibits the translation of the mecA gene which encodes the penicillin-binding protein 2a (PBP2a), a protein at the heart of the drug-resistance phenotype in MRSA. By reducing ...